BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q1 2020 Results - Earnings Call Transcript
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2020 Earnings Conference Call May 6, 2020 8:30 AM ET
Company Participants
John Bluth - Senior Vice President, Investor Relations and Corporate Communications
Jon Stonehouse - President and Chief Executive Officer
Charlie Gayer - Chief Commercial Officer
Megan Sniecinski - Chief Business Officer
William Sheridan - Chief Medical Officer
Anthony Doyle - Chief Financial Officer
Conference Call Participants
Jessica Fye - JPMorgan
Gena Wang - Barclays PLC
Tyler Van Buren - Piper Sandler
Liisa Bayko - JMP Securities LLP
Serge Belanger - Needham & Company
Maury Raycroft - Jefferies Group LLC
Operator
Good morning, ladies and gentlemen. And welcome to the BioCryst First Quarter 2020 Earnings Call. At this time, all the participant lines are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. [Operator Instructions] As a reminder, this conference call is being recorded.
I would now like to turn the conference over to your host, Mr. John Bluth at BioCryst.
John Bluth
Thanks, Whitney. Good morning and welcome to BioCryst first quarter 2020 corporate update and financial results conference call. Today’s press release and slides are available on our website.
Participating with me today are CEO, Jon Stonehouse; CFO, Anthony Doyle; Chief Medical Officer, Dr. Bill Sheridan; Chief Business Officer, Megan Sniecinski; and Chief Commercial Officer, Charlie Gayer. Following our remarks, we will answer your questions.
Before we begin, please note that today’s conference call will contain forward-looking statements, including those statements regarding future results, unaudited and forward-looking financial information, as well as the company’s future performance and/or achievements.
These statements are subject to known and unknown risks and uncertainties, which may cause our actual results, performance or achievements to be materially different from any future results or performance expressed or implied in this presentation. You should not place undue reliance on these forward-looking statements.
For additional information, including a detailed discussion of our risk factors, please refer to the company’s documents filed with the Securities and Exchange Commission, which can be accessed on our website.
I’d now like to turn the call over to Jon Stonehouse.
Jon Stonehouse
Thank you, John, and thank you all for joining us this morning. I hope you’re all safe and doing well. We are in an extraordinary position at BioCryst. The company is said to receive 3 approvals within the next 12 months for berotralstat.
We expect our first global approval in Japan in the second half of the year. We have a December 3 PDUFA date from the FDA. And in Europe, our MAA was validated in March and we expect approval about that time next year.
Right alongside these approvals, we have a pipeline in a molecule with our oral Factor D inhibitor, BCX9930 for complement-mediated diseases including PNH. We will share exciting data for 9930 in PNH patients with you for the first time today.
Let’s start with HAE and the value we expect to create with berotralstat. Patients are experiencing significant benefit in our clinical trials. Both physicians and HAE patients are consistently stating strong demand for our oral medicine in our market research. Based on the clinical response and the customer demand, we expect berotralstat will generate peak sales of north of $500 million.
And we announced yesterday that we have a new composition of matter patent that will extend our patent protection by 4 years to 2039. Add to that market potential for 9930 in an established market of more than $4 billion for treatment of complement-mediated diseases, and we see a significant opportunity for even greater value creation.
We have built the company focused on discovering, developing and commercializing oral drugs for rare diseases. We continue to advance our oral rare disease pipeline, which also includes BCX9250 for FOP, and additional discovery programs for other rare diseases. Beyond that, we’ve always believed our legacy antiviral programs play an important role in public health.
Galidesivir is a broad spectrum antiviral in a NIAID funded trial in COVID-19 patients. The experience and relationships we have developed across the U.S. government over the past decade, to support our antiviral programs continue to add value. We have contracts totaling $82 million of government funding for galidesivir and we’ve been able to move quickly with galidesivir into COVID-19 patients.
Patient dosing has begun in our clinical trial in Brazil and we look forward to generating data to determine if galidesivir could help in this global health emergency.
The disruption of the coronavirus pandemic has impacted every company. While the situation is fluid, for the most part, BioCryst continues to maintain its progress and timelines. We’re fortunate that the clinical trials and data to support our regulatory submissions for berotralstat were already completed at the time of the pandemic. As a result, our regulatory reviews are well underway, and our approval timelines and launch preparation activities remain on track.
Charlie and Megan have been building the global commercial and medical affairs teams and drug supply to support our upcoming launches. And they’ll provide an update. Then Bill will review our new data with 9930. Anthony will provide a Financial Review and I will wrap up by sharing our progress with galidesivir.
With that, I’ll turn the call over to Charlie.
Charlie Gayer
Thanks, John. We’ve been busy since the start of 2020. Our U.S. marketing and market access teams are complete and in action. And our regional sales leaders are preparing to hire representatives for individual sales territories in the third quarter. We’ve also added an experienced and efficient commercial team to execute our launch in key European markets.
Our launch preparations are moving forward smoothly, because of the work we completed last year, plus the focused efforts of our growing team. COVID-19 has not slowed us down. Megan will describe our readiness in more detail. But first, I’d like to review our market research and clinical data.
HAE attacks can be unpredictable and devastating, which explains why most patients in the United States had moved to prophylaxis. Several new injectable products have launched in recent years. So, patients and their physicians have experience switching to find the treatment that is best for them.
What many patients want now is to switch to oral prophylaxis to control their disease and reduce the burden of treatment. A big part of our strategy is to focus on that switch. Our market research and clinical data give us confidence in this strategy. We surveyed 100 patients and 175 HAE treating physicians and presented a profile based on top-line data from APeX-2. 59% of patients said they were very willing to use berotralstat, growing to 71% with the physician recommendation.
Notably, 79 of these 100 patients were already using Takhzyro, Haegarda or Cinryze, and most of them were also very willing to use berotralstat. Even among those very satisfied with their current injectable, half are very willing to use our oral drug. So why is that?
One reason may be that even with current injectables, most patients experience breakthrough attacks, patients on Takhzyro, for example, reported they still average about 0.5 an attack per month. The broader reason is patients want to reduce treatment burdens, such as storage, preparation and injection. Physicians understand the benefits of oral prophylaxis and expect to treat 41% of current patients with our oral drug in the future.
Our clinical data also show that many patients on injectable prophylaxis are likely to switch. As you can see on Slide 13, 44% of patients who enrolled in APeX-2 previously use C1 inhibitor prophylaxis. Since APeX-S opened in the U.S. last year, about 50% of newly enrolled patients were previously treating with Takhzyro, Haegarda or Cinryze. These numbers align with physician expectations reported in our research. Of the 41% share they anticipate for berotralstat, half come from switches from current prophylaxis.
Most patients in our trials are staying on berotralstat, because they really experience a benefit. Patients on 150 milligrams for a year in APeX-2 had a baseline average of 3 attacks per month, but averaged just 1 attack per month on treatment. Those switching from placebo to 150 milligrams after 24 weeks average only about half an attack per month.
Patients taking 150 milligrams in APeX-S have similar long-term results. And in 6 out of the 12 months, half or more are attack free. The experience from both of these trials shows the drug is safe and generally well tolerated. The main adverse events are gastrointestinal symptoms, but most of these are mild, self-limited and resolved within the first 2 months of treatment.
We recently interviewed 20 U.S. patients in the United States who have been enrolled in APeX-2 for over a year. The quotes on Slide 14 represent in their own words how berotralstat is helping them. You can see what a dramatic impact oral once-daily berotralstat is having on their lives. And we are excited to be so close to bringing our drug to HAE patients.
Now, I’ll turn it over to Megan to describe other important areas of our global launch readiness.
Megan Sniecinski
Thanks, Charlie, and good morning. We’re excited to be preparing for the launch of berotralstat. As John shared earlier, we have regulatory reviews ongoing by the 3 major agencies with approval timelines on track as planned.
Building on what Charlie highlighted, I’d like to touch on a few additional aspects of our launch readiness.
First, turning to our KOL engagement, which is a fundamental part of our pre-launch activities, across the U.S. and the EU, we continue to interact with the HAE medical community. These are important opportunities for scientific exchange and education on the clinical evidence supporting berotralstat.
Recently, as you may have seen, the AAAAI Annual Meeting, one of the major annual congresses for the HAE physician community was cancelled in March due to COVID. The congress shifted to hosting a virtual poster hall and in response our medical affairs team conducted a series of virtual sessions, which were a great opportunity to present and shares a data from our accepted posters with the scientific community.
In Europe, we also continue to interact with KOLs across the region as well as various patient organizations. Overall, HAE clinicians continue to be accessible via virtual calls in light of COVID. And we’re really pleased by the continued strong interest in learning more about our oral, once-daily treatment and its clinical program. From this work, we continue to see how better trials that will meet what is still a significant unmet need in the area of prophylactic treatment for HAE patients.
Next, moving to our supply readiness, having seen supply shortages for other HAE treatments in the past, BioCryst committed early on to ensuring that would not happen for berotralstat. We have dual source redundancy across the supply chain with 2 manufacturing sites for each stage. We are working with well-established PMO partners, and are well positioned in terms of supply today, because of our early investment. We already have more than ample product manufacturer for final packaging, and at this time, I’m happy to share that we don’t foresee any COVID impact to supply for a commercial launch.
Lastly, as Charlie mentioned, we’ve been fortunate to continue our APeX-2 and APeX-S clinical studies despite the current pandemic. Site monitoring transition from onsite visits to virtual consultations. And while many companies have stopped clinical trial operations, APeX-S screening continues and we even enrolled several patients in the U.S. last month alone. We think this continues to speak for the unmet need and demand for oral, once-daily prophy treatment option.
Our teams remain focused on preparing for successful launches in the U.S., the EU and through our partner Torii in Japan. With the potential to receive our first global approval in Japan, Torii launch preparations are actively underway, including building disease awareness and education. And as a reminder, with the PMDA approval we stand to receive a $20 million milestone payment contingent upon clearing a minimum price threshold following our MHLW pricing discussions.
It’s clearly a transformative year for BioCryst, as we look to what’s ahead of us in the next 12 months with our launches. In addition, we’re also focused on advancing our 9930 program. And Bill will walk you through that now. Bill?
William Sheridan
Thanks very much, Megan. We are very excited to share early data from the lowest dose cohort of treatment-naïve patients in our ongoing PNH proof-of-concept study with our oral Factor D inhibitor BCX9930. You will see from the 50 and 100 milligrams twice a day data that we are well on our way to a goal of achieving monotherapy.
We have seen dose related effects on control of hemolysis and clinical benefit. And in the healthy subjects multiple ascending dose study, the effect of 9930 on alternative pathway activity was superior at 200 milligrams and 400 milligrams twice a day compared to the lower doses. We’ve seen no safety signals. As you move next to the 200 and 400 milligram twice a day cohort in treatment-naïve PNH patients. These data tell us we should see complete control of hemolysis.
As a reminder, the design of the PNH study is shown on Slide 20. Cohort 1 is testing 50 and 100 milligrams twice a day, cohort 2 will test 200 and 400 milligrams twice a day. So where are we today? So far, we have enrolled treatment-naïve PNH patients that means they have not had C5 inhibitor drugs. 9930 is administered orally twice a day as monotherapy. 3 PNH patients have completed 14 days of dosing and 50 milligrams twice a day, followed by 14 days of dosing at 100 milligrams twice a day. At the day 28 visit, all 3 had clinical benefit assessed by the investigators from that drug, so all 3 continued on 100 milligrams twice a day in the long-term extension.
On Slide 21, you can see that these patients were seriously ill with PNH. One, had – previously had a cerebral vein thrombosis from the disease, the second required red cell transfusions, and the third had aplastic anemia and PNH.
In PNH patients show quite variable degrees of hemolysis and anemia, before treatment among our 3 patients, the LDH or lactate dehydrogenase level a sensitive marker of hemolysis range from over 800 to over 2,400 units per liter, or 3.7 to 11 times the upper limit of normal. And the degree of anemia was severe with hemoglobin of 6.0 to 8.2 grams per deciliter. All 3 patients had elevated reticulocytes counts, reflecting the bone marrow working overtime to try to get the hemoglobin up.
We are very encouraged by the laboratory and clinical responses that we’re seeing with the lowest doses of 9930, but 50 milligrams twice a day and 100 milligrams twice a day, the key biomarkers of hemolysis all improved. You can see the individual data on Slide 22. All 3 had clinically meaningful and dose dependent drops in LDH. The magnitude of effect is impressive, given that these sources are low and not optimized. Reticulocytes counts fill in all 3 patients. Total Bilirubin, another marker of hemolysis in PNH was elevated in 2 patients at baseline and normalized on 9930.
Previous studies of complement inhibitors have shown it takes about 8 weeks to see stabilization in hemoglobin with optimized doses. Hemoglobin is already increasing in our 4 week study window at our lowest doses, subject 2, for example, and at the study dependent on transfusions with a day 1 hemoglobin of 7.0 following a 2 unit red cell transfusion on day 15. This patient has now been transfusion free for 6 weeks, and the hemoglobin has risen from 8.9 post transfusion to 11.1 at week eight of study, while on 9930 at 100 milligrams twice a day.
The safety and tolerability profile of 9930 during the 28 day evaluation period is shown on Slide 23. Unlike our earlier Phase 1 experience in healthy volunteers, no patients developed a drug rash. There were no drug related serious adverse events. Most common observation was transient headache early in dosing, which is a well-recognized class effect of complement inhibitor treatment in PNH.
One unrelated serious adverse event occurred in the extension period, disseminated varicella infection that led to a patient death. This patient has PNH was treated with chronic corticosteroids and azathioprine, was a frontline healthcare worker, who is exposed to a subsequently contracted varicella. Varicella is known to be especially dangerous in patients taking steroids and other drugs that suppress lymphocytes. Based on this clinical history, we investigator determined the event was unrelated to 9930.
Our fourth treatment-naïve patient in cohort 1 was recently enrolled in South Africa, following completion of cohort 1, we expect to begin enrollment of C5 inhibitor naïve patients in cohort 2, testing 200 and 400 milligrams twice a day. And despite the COVID challenges, we continue to receive strong interest from investigators and patient efficacy to enroll PNH patients, who are poor responders to C5 inhibitors. We expect to beginning rolling for responding patients in the third quarter and report data from these patients by the end of the year. We’re very excited about this early data at 50 and 100 milligrams twice a day in PNH patients.
Also, we have completed the MAD cohorts for 200 and 400 milligrams twice a day in healthy subjects. The pharmacodynamic profile of these doses is clearly superior to the PD profile of 50 and 100 milligrams twice a day and there were no safety signals. The steady state results for individual healthy subjects in the MAD are shown on Slide 26 for both the AP Hemolysis and AP Weislab assays. Note that the assays were continued for 24 hours after the last dose, importantly for PNH treatment, the higher doses provide more consistent coverage, especially in the period beyond 12 hours after the dose.
The main values as shown on Slide 27, at both 200 and 400 milligrams twice a day, AP activity was blocked by more than 98% in both assays throughout the dosing interval of steady state. When you see the level of complement suppression, we have at 200 and 400 milligrams, you may ask if this could be the profile of once-a-day drug, it might be. And we do plan to explore once daily dosing in the healthy subject MAD study, as well as wrapping up the study by characterization of clinical pharmacology of 9930 with additional cohorts of testing super therapeutic doses.
So what have we learned about dose? First, there is a clear dose response at 50 and 100 milligrams twice a day in treatment-naïve PNH patients with clinical benefits. Second, PD results of 200 and 400 milligram twice a day doses in healthy subjects were superior to the lower doses. Therefore, we plan to begin the C5 poor responder cohort at that dose level i.e., 200 milligram, 400 milligram.
Our goal is to develop BCX9930 as an all monotherapy for PNH and other complement mediated disease. The PNH patient and MAD healthy subject data we share today strongly support that goal. We’re excited to complete a proof-of-concept study and to speak with regulators about our next steps in PNH and other diseases caused by dis-regulation of complement.
Jon Stonehouse
Thanks, Bill. As you can imagine, we are very excited about these results and getting closer to our goal of having an oral Factor D inhibitor that has great efficacy as monotherapy. With $115 million we reported at the end of Q1, we have sufficient capital to get us through this year and into the early part of next year. This capital funds completing our proof-of-concept study with 9930 and fully investing in the launch preparation for berotralstat.
We also have a plan that gives us flexibility to bring in additional capital into the company. And I’m very pleased to introduce our new CFO, Anthony Doyle to describe that for you. We conducted a comprehensive nationwide search with some exceptional candidates and Anthony stood out among them. He spent the past 6 years as the CFO of a Global CRO, and spent the majority of his career prior to that rising through the ranks at GE.
With that intro, I’ll now turn the call over to Anthony.
Anthony Doyle
Thanks, Jon. It’s certainly an exciting opportunity for me and a great time to be joining BioCryst. With the upcoming commercial launch of berotralstat, a strong pipeline behind it, including an oral Factor D inhibitor, and opportunities to help them the coronavirus pandemic with galidesivir, the company has tremendous runway for success in the near future. You can find the financial results from the first quarter detailed in the press release. But I did want to highlight where we are with the balance sheet and our approach to capital in the upcoming months.
As Jon noted on the cash side, we ended Q1 with $115 million based on the outlook that we’ve provided. This gives us runway through 2020 and into early 2021. We have several additional potential capital sources to provide financial flexibility as we progress through the year. We expect to trigger up to $20 million milestone with – from Torii. Also our data from BCX9930 provides options to add capital such as a partnership to advance that program. And additionally, we’re evaluating royalty and/or debt financing for berotralstat that would bring in capital at approval to fund the launch.
Stepping into this role, I’m very much looking forward to generating revenue starting early next year with a product that we believe will have peak sales now extended through 2013 with our new patent of greater than $500 million, and a very dynamic pipeline behind us. Jon?
Jon Stonehouse
Thanks, Anthony. I also want to update you on our progress with galidesivir are nucleoside RNA polymerase inhibitor, which we are testing as a potential treatment for COVID-19. In April, we announced that we had opened a randomized double-blind placebo-controlled clinical trial of galidesivir in COVID-19 patients in Brazil. This study is funded by NIAID. The trial has started with patients currently enrolling into Part 1, the dose ranging part of the trial.
We look forward to updating you on what we see in Part 1 and how that data informs our dose selection and progress in Part 2. The rationale for studying galidesivir in COVID-19 is that it’s an adenosine nucleoside analog RNA polymerase inhibitor that’s demonstrated broad spectrum antiviral activity.
We’ve conducted in vitro test against more than 20 RNA viruses in 9 different families, including the corona viruses that cause MERS and SARS. In vitro testing of galidesivir against SARS-CoV-2, the virus that causes COVID-19, is also underway. And we are working with our government partners and collaborators to identify potential animal models that could provide additional data against experimental SARS-CoV-2.
At the end of the day, clinical data from randomized placebo-controlled trial will provide the best information on the benefit the drug has for COVID patients. And we’re looking forward to getting that data as quickly as possible.
So let me wrap up where I started. BioCryst is in an extraordinary position. We have 3 approvals coming within the next 12 months for berotralstat. The strong clinical data and market demand from HAE patients and physicians have led us to a forecast north of $500 million in peak sales for this product.
In addition, we have a pipeline in a molecule with 9930. And the early data we shared today adds to our confidence in the success of this program across multiple complement-mediated diseases. And our antiviral programs are positioned to help address a global health emergency and add additional value.
I want to close by thanking our team at BioCryst, and all of our investigators, patients and collaborators around the world, who have made this progress possible. Despite the significant current disruptions and challenges in their own daily lives. We wouldn’t be where we are today without you, so thank you.
With that, we’ll turn it over to the operator for questions.
Question-and-Answer Session
Operator
[Operator Instructions] Your first question is from the line of Jessica Fye with JPMorgan.
Jessica Fye
Hey guys, good morning. Thanks for taking my questions. I had a couple on the 9930 data. First, why do you think reticulocytes appear to rebound after they initially fall on treatment? And second, sounds like there were no rashes observed in the first 3 patients. Was there even any transient rash? And I’m curious if you have a hypothesis for why that was not seen here when the healthy volunteer data would have suggested you might.
William Sheridan
Yeah, hi, Jessica. It’s Bill. Thanks for the question. The reticulocytes are going to remain active and elevated while the subjects are anemic. So as we see the data mature in the subsequent weeks and see the hemoglobin come up, you’d expect it to come and stay into the normal range. And with regard to the rash, no, we didn’t see any mild rash and no rash at all in the first 3 subjects.
Why? That’s an interesting question. In the berotralstat program, we saw a similar phenomenon where we had a higher incidence of rash in healthy subjects compared to people getting HAE. And we’ll see how it evolves.
Jessica Fye
Okay, great. And can I just ask you a couple on galidesivir as well? How many sites are open in Brazil and when should we anticipate that data? And I think there’s also been some reports on the web saying galidesivir has shown activity in vitro against the current coronavirus. The press release makes it sound like you’re still evaluating that. Have you seen any early indications of activity?
Jon Stonehouse
Yeah. So on the sites, off the top of my head, I think there are 3. But I’ll have to confirm that and get back to you. I think there are 3 sites in Brazil. And we’re working on getting a fourth. With regard to the SARS-CoV-2 in vitro testing, don’t want to comment until that work is fully completed. And it isn’t and when it is, we will report that data.
Jessica Fye
And is there any timeline for the clinical data?
Jon Stonehouse
That’s a hard one to predict. The pandemic in Brazil is pretty widespread and pretty active right now. And so, we’re dosing patients. We’re in part one. But it’s really, really hard to predict. The more sites that we have open in Brazil, the faster we’ll be able to enroll and we’re doing as much as we can to move it as quickly as we can.
Jessica Fye
Great, thank you.
Jon Stonehouse
You’re welcome.
Operator
Your next question is from Gena Wang with Barclays.
Gena Wang
Thank you for taking my questions. And just want to follow the rash question. I want to confirm for this cohort data, the PNH patients cohort, you do not use penicillin.
William Sheridan
That’s right. Prophylaxis against [nicirial] [ph] infections with vaccination. And, looking at the whole body of evidence here, we’re thrilled with the data that we have in the first 3 subjects in this study, not just the absence of rash, in a serious disease like this, even if patients did get a rash, we’d treat through it. The benefit here is outstanding. So there was no penicillin, [nicirial] [ph] prophylaxis with vaccination.
Gena Wang
Okay. And for all the trials you would not use penicillin, right, for the all the proposed new cohorts?
Jon Stonehouse
She’s asking the future.
William Sheridan
Yes, yeah. I think that we’re completely relaxed about the co-administration of penicillin or any other antibiotic with this drug by the way. So it’s not really an issue for us. We figured out that there was a drug rash in the healthy subjects, which was benign. But clinically and pathologically, and we treated through a couple of cases. And, there’s no protocol requirement to use penicillin at all. If people need antibiotics for whatever reason, they can get them.
Jon Stonehouse
But we’ll use the vaccine…
William Sheridan
Yeah, the vaccine is the approach, yeah.
Gena Wang
I see. I think the reason I’m asking, just wanted to see how likely the rash is due to penicillin. And would there be any – eliminate any unnecessary [tuck-on based data] [ph].
William Sheridan
Huh-uh.
Gena Wang
Yeah. So I think – that was the reason I’m asking.
Jon Stonehouse
Yeah, no, we can’t say that it’s the penicillin difference between the healthy volunteers and the PNH patients. The fact of the matter is we’ve had 3 patients with PNH. And we’ve seen no rash. And as Bill mentioned in his comments, this is a phenomenon that we saw in HAE with berotralstat as well that we saw rash at a higher incidence in the healthy volunteers and way lower incidence in HAE patients. We’ll see as we go.
Gena Wang
Okay. And then, another data question. Slide 26, just wondering, do you have 1 patient on the left side, only using AP hemolysis, that you have 1 patient that’s regarding 200 milligrams to 400 milligrams. You have 1 patient basically had increase of LDH – hemolysis inhibition rebound. There’s one outlier there.
And then, on the right side, when we’re using Weislab assay, you have additional patient also showed up on the outlier later. Just wondering if you can give a little bit more color on basically these 2 outliers, any more additional color on the baseline or anything that could contribute to this rebound of hemolysis inhibition?
William Sheridan
Sure, thanks for the question. I really love this chart. It shows a spectacular better consistency, comparing 200 milligrams and 400 milligrams versus 50 milligrams and 100 milligrams. And the reason that we’ve shown the data this way, is because we’ve done the assay through 24 hours after the last dose with a twice-daily dosing regimen.
So all the way through 16 hours, there’s almost complete suppression of AP activity, whether or not you’re measuring it in the Weislab assay with a hemolysis assay. Of course, as the drug disappears from the system over the next period, eventually it will get to levels where it’s not suppressing, complement enough, and eventually you will get positive results in the assay. And we’re starting to see that in the odd individual here and there. This a great chart.
Jon Stonehouse
But it’s a twice-a-day drug, so it covers up to 16 hours, which everybody is fantastic.
William Sheridan
Yeah, this is a great chart.
Gena Wang
Yeah. So I think the reason I’m asking is to see how likely that could be a QD drug if – who are these patients that actually like – what are the – any differences in terms of baseline, or any other colors there?
William Sheridan
I think it’s – with this data, we don’t know yet, but it’s obviously encouraging us to study once-daily dose, which is what exactly we’re going to do in the MAD. And we’ll have to figure out what doses might be able to achieve that.
Gena Wang
Okay, thank you.
Operator
Your next question is from Tyler Van Buren with Piper Sandler.
Tyler Van Buren
Hey, guys. Good morning. Thanks for taking the questions. It’s exciting to see the initial 9930 PNH data. I guess, I just wanted to ask you guys to make some comparisons potentially to the Phase 2 [the next] [ph] data for the other oral Factor D. It’s early days, of course, and small number of patients. But they seem to compare favorably.
Are there any noticeable differences that you guys would point out? And then, the second question, on the once-daily dosing, what do you see in the MAD study in order to have confidence that you can use that in patients and incorporate into clinical program?
William Sheridan
Okay, so, first of all, I’d say we’re incredibly happy with the data we have in the first 3 subjects here. The LDH, reticulocytes, bilirubin, all going in the right direction and really, really strong drops from pre-treatment. And in a short period, the hemoglobin is starting to rise. And I didn’t mention this on the call. But the PNH clone size in the 2 subjects where it was fairly low has come up pretty dramatically, even in the first 2 weeks on 50 milligrams twice-a-day. It’s pending for later.
But in terms of comparisons with other studies, I would direct people to look at the very earliest studies with other agents. And our data is at least as good as anybody else’s, especially when you’re looking at people who are severely anemic at baseline. So this is a tremendous result.
Jon Stonehouse
Hey, Bill, I would add on the comparisons. See, one of the challenges in comparisons is where do patients start. As Bill said in his remarks, these were really sick people. And so, instead of looking at the absolute number, I think that percentage change is important to compare. And I think we did fantastic on that front.
William Sheridan
And with regard to once-a-day dosing, it’s the persistence of pharmacodynamic effect through 24 hours in the great majority of people who had 200 milligrams every 12 hours or 400 milligrams every 12 hours. That is striking, and gives us absolutely good, clinic – some quality reason to go and test once-daily dosing. And we’ll do that and see what we get, and then we’ll be in a position to understand whether we want to include that in a PNH cohort.
Tyler Van Buren
Great. Thank you.
Jon Stonehouse
You’re welcome.
Operator
Your next question is from Liisa Bayko with JMP Securities.
Liisa Bayko
Hi, there. Thanks for taking the question. Can you maybe just go through some sort of comparing and contrasting of galidesivir versus remdesivir in terms of kind of where they’re similar, where you see opportunities to differentiate; I know the molecules themselves are quite similar maybe you talk about exposure and other attributes?
Jon Stonehouse
Yeah, let – I’ll start and then Bill can get into some of the specifics. This is not like a normal market, where you’re taking market share from one product to another, the government and we’ve seen this in smallpox and other areas that the government needs multiple weapons in the arsenal to combat viral outbreaks like the one we’re currently experiencing. And so we see the ability to have both remdesivir and galidesivir in strategic national stockpiles around the globe.
And you’ve even heard from some of the government officials that more needs to be done. Cocktails of drugs need to be – studies need to be done, and so there’s plenty of room for another RNA polymerase inhibitor like galidesivir.
William Sheridan
Yeah, in terms of comparison that both galidesivir versus remdesivir nucleoside analogs. They both adenosine analogues structurally, obviously, they’re different. It’s really good to see the emerging data on remdesivir coming out positive. That’s good for the world. And it’s good for the field. And it’s good for nucleoside analogs. And we’re very happy to we started that study. In other aspects, I think it’s just not enough information to make any detailed comparisons.
Liisa Bayko
Okay. In terms of talking further down the line about pre-launch activities for HAE. Can you maybe talk about kind of what your plans are, how much heavy lifting in terms of hiring and building out the salesforce infrastructure, do you plan to do ahead of approval?
Jon Stonehouse
Charlie?
Charlie Gayer
Yeah. So thanks for the question. And as I mentioned in my comments were – our in-office team is complete at this point, our sales leadership team regional sales leaders are complete, and we’re getting ready for the hiring the salesforce. So we’ll be doing that in Q3.
Jon Stonehouse
And Megan, you want to hit the medical affairs piece?
Megan Sniecinski
Sure, Jon, I think from a medical affairs perspective and sort of shared in my remarks, we got a full team deployed, that are actively engaging with the KOLs. And similar to Charlie, we’ve been really encouraged by the talents we’ve brought into our teams and their experience in the pre-launch launch phase, rare diseases and as well as specifically HAE. So I know he and I are just feeling really excited about where we are today and looking forward to continuing to do the important work in the coming months and ready for a launch later this year.
Jon Stonehouse
Yeah, I can’t tell you – Megan’s points are really important one. I can’t tell you the number of people that have come into the commercial organization and medical affairs, and said they came in because we have an oral drug for HAE. So that tells you something.
Liisa Bayko
And can you talk about drug supply there, where you manufacture and then just kind of FDA, are they on track with scheduled inspections and that kind of thing? I’m just thinking about due to travel restrictions. I’d just be curious about some color and how that’s all tracking?
Jon Stonehouse
Megan, you want to take the manufacturing question?
Megan Sniecinski
Sure. Sure. So Liisa, I – so couple of things to highlight. I think the fact that BioCryst made that early investment in the dual source redundancy throughout the chain has positioned us well and we were able to, again do a lot of work before COVID. So we really feel like we’ve got ample supply and are in great shape of what we need for a successful launch and everything in terms of what we need to be on track for the PDUFA date in December from a supply perspective.
Jon Stonehouse
And one other thing that we’ve started to see even with FDA, we saw with the Japanese PMDA is virtual inspections are starting to take place by both agencies. So that’s encouraging to.
Liisa Bayko
That’s interesting. How does that work?
Jon Stonehouse
Through technology.
Liisa Bayko
Okay, for the real inspection or something.
Jon Stonehouse
Yeah. Yeah. Yeah. Well, you remember a lot of its document sharing and answering questions and…
Liisa Bayko
Okay. Understood. Okay. And then just to follow-up on Gena’s question, QD looks like a real possibility. You don’t really have it on Slide 20 kind of outline with when you might explore QD, can you maybe speak to that? And then, as – and this is my last question. For 9930, as you think about other indications, so what makes sense maybe as a second and a third indication to explore and when might you start working on that? Thank you.
William Sheridan
Sure. So the multiple ascending dose healthy subject study is still open. So we plan to study QD, as the rest of the year unfolds. And then we’ll look at the data and decide whether it justifies looking added in the PNH study, one way or another.
Jon Stonehouse
The other was on indications. And…
William Sheridan
So the indication landscape here is rich. So one of the incredible things about the Factor D inhibitor that’s potent a specific like this, is that the number of diseases can treat and make a huge impact on patients’ lives is fantastic. So, for example, they are C3 glomerulonephritis dense deposit disease, no various nephropathy iga and the property. There are a bunch of things in the field of nephritis. It will make those decisions as we meet with regulators and develop the program.
Jon Stonehouse
Yeah. And you could very well see that we do a broad clinical development program offer around multiple indications. And when we talk about the excitement of this data, it’s not just PNH with the data that we have we’re excited about all the complement-mediated diseases.
William Sheridan
There’s one particular difference between PNH and all the other diseases. Is that PNH is marked by the hemolysis, right. None of the others are. And the scheduling in nephritis, I can easily see is once a day with the data that we currently have.
Liisa Bayko
Very exciting. Thanks a lot for answer my question.
Jon Stonehouse
You’re welcome.
Operator
Your next question is from Brian Abrahams with RBC Capital.
Unidentified Analyst
Hi, hello. This is Leo on for Brian. I just had another question on the AE profile of the drug. I’m just curious, so the patient that had died, were they still on the drug post 28 days, and where they also the same patient required transfusion. And can you remind us if the Factor D inhibition can also increase susceptibility to viral infections? And if it does, how that might play out in terms of impacts the clinical trial recruits in the middle of pandemic?
William Sheridan
Sure. So this patient, who unfortunately contracted varicella had never had a vaccination and had never had chickenpox and was a healthcare worker. So that is an unfortunate combination of circumstances and this person was taking corticosteroids. Chronic corticosteroids is the number one risk factor for getting disseminated varicella. Of course, we’ve done very extensive diligence around this, including extensive literature searches, looking at congenital complement deficiencies. There’s not a single case of disseminated varicella with any sort of congenital complement deficiency. Extensive literature searches around eculizumab. There was one reported case not of a death, but a young boy who had hemolytic uremic syndrome from Shiga toxin and got varicella and recovered, who is getting eculizumab.
And then in the FDA adverse event reporting system, we’ve extensively come through that looking at a whole variety of drugs, but specifically, of course, eculizumab. And there is one individual who was also getting corticosteroids and mycophenolate mofetil. So all of the evidence here points towards corticosteroids, of course, we want to play this very safe. So we’re changing the protocol to make sure that people are immune against chickenpox.
Jon Stonehouse
Yeah. And then your question about recruitment, we had a 4 patient, as Bill said in his prepared remarks coming to the study last week. So there’s still a lot of enthusiasm build the investigators are still really enthusiastic about the drug and the trial, and we don’t expect it to impact recruitment at all.
William Sheridan
So in summary all of that diligence says that if you seriously damage lymphocytes that’s what sets up the risk here. And the complement system – inhibiting the complement system doesn’t do that.
Unidentified Analyst
Okay. Thank you.
Operator
[Operator Instructions] Your next question is from the line of Serge Belanger with Needham & Company.
Jon Stonehouse
Serge? Whitney, we may want to go to the next one. Hold on, hold on. They are.
Serge Belanger
The mute button was not my friend. A couple of questions on 9930. First, Bill you reported, I think on Slide 26, that you achieve the over 98% sustained alternative pathway suppression at the doses of 200 and 400 milligrams in the multiple ascending dose part of the trial and healthy volunteers. How does that compare to the lower dose of 50 and 100?
William Sheridan
So if we look at the chart, what matters is the consistency. So if you look at the 12-hour time point, you can see that there are many individuals at 50 and a couple of individuals at 100, who have more than 5% residual activity as the alternative pathway in those assays. So what we want to achieve here is 100% of the subjects having more than 98% suppression, which is exactly what you get at 200 and 400 milligrams.
Jon Stonehouse
And the slide number on that, Bill?
William Sheridan
26, yeah. Slide 26. So it’s all about the consistency of effect. So the second thing here is, as we mentioned a couple of times on the call already, the persistence of effect beyond 12 hours is especially important in PNH, because you want to make sure that you have around the clock coverage.
Serge Belanger
Okay. And then on galidesivir, you talked about an $82 million contract with BARDA and NIAID. Where are you vis-à-vis that the span of that contract? And are there any ongoing efforts to expand that as the trial in Brazil gets underway here?
Jon Stonehouse
So we’re about halfway through that total money. I think, it’s more largely consumed on the NIAID side than the BARDA side. And of course, we’ll continue to look at other opportunities to get proposals to the government to add additional money, either to this contract or a new contract. Yeah.
Serge Belanger
Okay. And then, I guess, just one berotralstat for Charlie, as you start thinking of negotiations for a label, what are the key aspects of the label you’ll be looking for as well, key aspects of the APeX data that you’ll want to see on the berotralstat label?
Charlie Gayer
Yeah. So thanks for the question. So obviously, we’ve submitted a draft label and we kind of – we expect to have a label that’s, that’s consistent with the other products in the marketplace. And so, we’re in based on what we’ve seen so far, we’re confident and that’s what we’ll get.
Serge Belanger
Okay. Thank you.
Jon Stonehouse
You’re welcome.
Operator
Your next question is from the line of Maury Raycroft with Jefferies.
Maury Raycroft
Hi, good morning, everyone. And thanks for taking my questions. I just had a quick one on 9930 for patient 2. It looks like that patient was getting transfusions at baseline and needed one while on treatment. Do expect the patient may need fewer transfusions over time that, as the patient stays on 9930.
William Sheridan
That individual had a transfusion on day 15 Maury, and at week 8, the hemoglobin has now risen from post-transfusion of 8.9 or something like that to 11.1. Anecdotally, when the patients have made clinic visits, we’ve had comments relayed by the principal investigators at the site. So this is the best they’ve ever felt.
So you got to remember that in South Africa, the C5 inhibitors are not approved. So the symptoms of the disease have been severe. And they feel fantastic on the drug, which is – it’s anecdotal, but it’s really great to hear. And the fact that we’re seeing this at low doses that are not optimized yet is really, really encouraging.
Maury Raycroft
Got it. Okay. And then for patient 3, it seems like the efficacy response was not as robust as the other patients. Just wondering if that’s related to the patient’s baseline, aplastic anemia, and you think the higher dose could overcome and get the patient – get this type of patient to respond better?
William Sheridan
I think that’s a really interesting question. This patient does have a combination, aplastic anemia and PNH. So the ability of the bone marrow to respond is going to be more limited under those circumstances, but also regarding that patient the hemoglobin has continued to rise. And I can’t predict where it’s going to go ultimately. But we are amending the protocol to allow dose escalation in the extension phase for these subjects who are going – who are completing cohort 1. So we will be able to get the opportunity to see what happens when we increase the dose.
Maury Raycroft
Got it. And last quick question, just regarding the new patent for the crystalline salt forms berotralstat. Will any of the new forms be used in the commercial setting? And have you done bioequivalence testing with the new forms?
Jon Stonehouse
It’s the API. So it’s in the commercial formulation as we speak, and so it’s automatic.
Maury Raycroft
Got it. Okay. Okay, thanks for taking my question.
Operator
Your final question is from the line of Gena Wang with Barclays.
Gena Wang
Thank you for taking my follow-up. I think I forgot to ask about headache question. So the 3 of 3, like all 3 subjects had moderate headache. We understand this is likely the drug class, since we saw so for [a7 weeks] [ph] had the headache. Just wondering if you can give a little bit more color regarding the onset, and then you did mention a little bit, less than 1 to 3 days, like if you can give a little bit more color on the headache regarding onset, how long it lasts and how it was resolved.
William Sheridan
Sure. The onset is very quick in the first day or two. The duration is a few hours, to less than a couple days. And what’s really striking about this is 3 out of 3, that means that in every single individual, we’re immediately starting to control hemolysis, because the reason these people get headache when they start complement inhibitors, is because you release nitric oxide from being scavenged.
And without going into all of the details, the investigators in the field have worked this out. So it’s a class effect of getting on top of intravascular hemolysis with the drug and you know that it disappears very quickly.
Gena Wang
So, any other drug to alleviate the headache?
William Sheridan
So this has been reported previously with eculizumab and Ultomiris, and other complement inhibitors that are investigational.
Jon Stonehouse
So it’s a sign that’s going to work.
William Sheridan
Exactly. And then, what we found too is that it is in vivo evidence that the drug is working, yes.
Gena Wang
Yeah. So I understand that part, but do you need any like, say, any like prescription drug or anything to mitigate this headache?
William Sheridan
No, this is the Tylenol.
Gena Wang
Okay. Okay. Okay, thank you.
Operator
I am showing no further questions at this time. I will now turn the call back to Mr. Stonehouse for any closing remarks.
Jon Stonehouse
Thank you, Whitney. As I said at the beginning, we are transforming this company with 3 launches, 2 of them coming this year, generating – starting to generate real revenue starting next year, that the data that we have with 9930 we couldn’t be more excited about. And that gives proof that we have a drug that can be used in complement-mediated diseases across the board beyond PNH.
So we got a tremendous pipeline, and then add to that the opportunity to play a role in the global pandemic, with our antiviral, we just couldn’t be in a better spot. And so, we’re super-excited about where we sit. We’re going to be working really hard to continue to move our programs for get ready for the launches and approvals. And we will keep you posted along the way.
Thank you for your interest, and stay safe, and have a great day.
Operator
Ladies and gentlemen, this concludes today’s conference. Thank you for participation and you have a wonderful day. You may all disconnect.
- Read more current BCRX analysis and news
- View all earnings call transcripts
Recommended For You
Comments (6)
